Gel Med's Gel Drug Delivery System (GDDS) is a novel transmucosal drug delivery method for systemic or local delivery of drugs that heretofore could only be delivered by injection. The GDDS is based on the discovery that receptor mediated endocytosis is enhanced when a drug is delivered in a viscous solution with a formulation viscosity that approximates the intracellular viscosity of the mucosal target cells. The GDDS does not require potentially toxic permeation enhancers or chemical modification of the active agent to facilitate delivery.

• GDDS Inventors
  Robert Langer, Ph.D., MIT
  David Edwards, Ph.D. (while at Penn State)
  Daniel Deaver, Ph.D. (while at Penn State)

• GDDS drugs administered to mucous membranes are transcytosed to the abundant capillary networks underlying them, thereby allowing the drugs to rapidly enter the bloodstream. This delivery route avoids first pass metabolism in the gut and liver.

• The GDDS offers many advantages over multiple subcutaneous or intramuscular injections currently required to treat a variety of conditions such as infertility, diabetes, multiple sclerosis and cancer.

• GDDS Advantages
  Painless, non-invasive administration
  Convenient delivery, no device is required
  Improved patient compliance and patient outcome